Odanacatib pharmacokinetics in subjects with mild or moderate hepatic insufficiency and healthy controls
Latest Information Update: 13 Nov 2013
At a glance
- Drugs Odanacatib (Primary)
- Indications Male osteoporosis; Postmenopausal osteoporosis
- Focus Pharmacokinetics
- Sponsors Merck & Co
- 13 Nov 2013 New trial record
- 08 Oct 2013 Results presented at the 35th Annual Meeting of the American Society for Bone and Mineral Research.